{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T05:08:27Z","timestamp":1791608907414,"version":"4.3.4"},"reference-count":70,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2016,6,24]],"date-time":"2016-06-24T00:00:00Z","timestamp":1466726400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["P01 AG19783"],"award-info":[{"award-number":["P01 AG19783"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000905","name":"Commonwealth Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000905","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J American Geriatrics Society"],"published-print":{"date-parts":[[2016,8]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate frequency of use of two anti\u2010dementia drug classes approved for treatment of symptoms, whether populations most likely to benefit are treated, and correlates of treatment initiation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Nationally representative cohort study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Fee\u2010for\u2010service Medicare.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>Elderly adults with dementia enrolled in Medicare Parts A, B, and D in 2009 (N = 433,559) and a subset with incident dementia (n = 185,449).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Measurements<\/jats:title>\n                    <jats:p>Main outcome was any prescription fill for antidementia drugs (cholinesterase inhibitors (ChEIs) or memantine) within 1 year.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Treatment with antidementia drugs occurred in 55.8% of all participants with dementia and 49.3% of those with incident dementia. There was no difference between ChEIs and memantine use according to dementia severity (measured as death within first year or living in residential care vs in a community setting) even though memantine is not indicated in mild disease. In incident cases, initiation of treatment was lower in residential care (relative risk (RR) = 0.82, 95% confidence interval (CI) = 0.81\u20130.83) and with more comorbidities (RR = 0.96, 95% CI = 0.96\u20130.96). Sixty percent of participants were managed in primary care alone. Seeing a neurologist (RR = 1.07, 95% CI = 1.06\u20131.09) or psychiatrist (RR = 1.17, 95% CI = 1.16\u20131.19) was associated with higher likelihood of treatment than seeing a primary care provider alone, and seeing geriatrician was associated with with lower likelihood (RR = 0.96, 95% CI = 0.93\u20130.99). Across the United States, the proportion of newly diagnosed individuals started on antidementia treatment varied from 32% to 66% across hospital referral regions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Antidementia drugs are used less often in people with late disease, but there is no differentiation in medication choice. Although primary care providers most often prescribe antidementia medication without specialty support, differences in practice between specialties are evident.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jgs.14226","type":"journal-article","created":{"date-parts":[[2016,6,25]],"date-time":"2016-06-25T21:43:01Z","timestamp":1466890981000},"page":"1540-1548","source":"Crossref","is-referenced-by-count":71,"title":["Treatment Patterns with Antidementia Drugs in the United States: Medicare Cohort Study"],"prefix":"10.1111","volume":"64","author":[{"given":"Daniela","family":"Koller","sequence":"first","affiliation":[{"name":"Department of Health Services Management Munich School of Management Ludwig Maximilian University of Munich Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tammy","family":"Hua","sequence":"additional","affiliation":[{"name":"Dartmouth College Hanover New Hampshire"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie P.W.","family":"Bynum","sequence":"additional","affiliation":[{"name":"Dartmouth Institute for Health Policy and Clinical Practice Geisel School of Medicine Dartmouth College Lebanon New Hampshire"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,6,24]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2012.11.007"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31828726f5"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2012.11.006"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsa1204629"},{"key":"e_1_2_6_6_1","unstructured":"Public Law 111\u2010375\u2010Jan 4 2011. National Alzheimer's Project Act. USA 2011."},{"key":"e_1_2_6_7_1","first-page":"CD005593","article-title":"Cholinesterase inhibitors for Alzheimer's disease","volume":"1","author":"Birks J","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_6_8_1","first-page":"CD006504","article-title":"Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease","volume":"3","author":"Rolinski M","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_6_9_1","first-page":"CD004746","article-title":"Galantamine for vascular cognitive impairment","volume":"4","author":"Birks J","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-148-5-200803040-00008"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-148-5-200803040-00009"},{"key":"e_1_2_6_12_1","unstructured":"Federal Drug Administration.FDA Approves Expanded Use of Treatment for Patients with Severe Alzheimer's Disease 2006[on\u2010line]. Available athttp:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/2006\/ucm108768.htmAccessed January 3 2016."},{"key":"e_1_2_6_13_1","unstructured":"Medscape.FDA Approves Exelon Patch for Severe Alzheimer's 2013[on\u2010line]. Available athttp:\/\/www.medscape.com\/viewarticle\/807062Accessed January 3 2016."},{"key":"e_1_2_6_14_1","first-page":"CD003154","article-title":"Memantine for dementia","volume":"2","author":"McShane R","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2011.69"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(07)70195-3"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pec.2007.10.010"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.070804"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.43.18"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2010.03040.x"},{"key":"e_1_2_6_21_1","unstructured":"NICE Guidelines (CG42). Dementia: Supporting People with Dementia and their Carers in Health and Social Care[on\u2010line]. Available athttps:\/\/www.nice.org.uk\/guidance\/cg42\/chapter\/1-guidance#interventions-for-cognitive-symptoms-and-maintenance-of-function-for-people-with-dementiaAccessed January 3 2016."},{"key":"e_1_2_6_22_1","unstructured":"Medicare Payment Advisory Commission.A Data Book: Health Care Spending and the Medicare Program 2013[on\u2010line]. Available athttp:\/\/www.medpac.gov\/documents\/publications\/jun14databookentirereport.pdfAccessed January 3 2016."},{"key":"e_1_2_6_23_1","unstructured":"Centers for Medicare and Medicaid Services.Part D Program Analysis 2013[on\u2010line]. Available athttp:\/\/www.cms.gov\/Medicare\/Prescription-Drug-Coverage\/PrescriptionDrugCovGenIn\/ProgramReports.htmlAccessed January 3 2016."},{"key":"e_1_2_6_24_1","unstructured":"HargraveE HoadleyJ MerrellKet al.Medicare Part D 2008 Data Spotlight: Ten most common brand\u2010name drugs[on\u2010line]. Available athttp:\/\/kff.org\/medicare\/issue-brief\/medicare-part-d-2008-data-spotlight-tenAccessed January 3 2016."},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/gps.2275"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.18.2148"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2318-13-37"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-146-11-200706050-00006"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.294.15.1934"},{"key":"e_1_2_6_30_1","unstructured":"U.S. Food and Drug Administration.FDA Alert. Information for Healthcare Professionals: Conventional Antipsychotics 2005[on\u2010line]. Available athttp:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm124830.htmAccessed January 3 2016."},{"key":"e_1_2_6_31_1","unstructured":"U.S. Food and Drug Administration.Public Health Advisory. Deaths with Antipsychotics in Elderly Patients with Behavioral Disturbances 2008[on\u2010line]. Available athttp:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm124830.htmAccessed April 4 2016."},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.2165\/11536760-000000000-00000"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.1999.tb04580.x"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(02)00452-3"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(03)00133-1"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-2009-1099"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1475-6773.2007.00748.x"},{"key":"e_1_2_6_38_1","first-page":"311","article-title":"Are general practitioners able to accurately diagnose dementia and identify Alzheimer's disease? A comparison with an outpatient memory clinic","volume":"50","author":"Hout H","year":"2000","journal-title":"Br J Gen Pract"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-014-0183-2"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1177\/1533317513504611"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.53.6.1292"},{"key":"e_1_2_6_42_1","unstructured":"Lexi\u2010Data Basic database (Lexicomp).Denver CO:Cerner Multum. Available athttp:\/\/www.lexi.com\/businesses\/solutions\/clinicaldecision-supportAccessed January 3 2016."},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(87)90171-8"},{"key":"e_1_2_6_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(92)90133-8"},{"key":"e_1_2_6_45_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwh090"},{"key":"e_1_2_6_46_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1991.00400090107019"},{"key":"e_1_2_6_47_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1997.00440350031003"},{"key":"e_1_2_6_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2012.03922.x"},{"key":"e_1_2_6_49_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa066583"},{"key":"e_1_2_6_50_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0035185"},{"key":"e_1_2_6_51_1","doi-asserted-by":"publisher","DOI":"10.1159\/000111534"},{"key":"e_1_2_6_52_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-012-1451-y"},{"key":"e_1_2_6_53_1","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e328344c600"},{"key":"e_1_2_6_54_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2012-002080"},{"key":"e_1_2_6_55_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-11-190"},{"key":"e_1_2_6_56_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2014.4103"},{"key":"e_1_2_6_57_1","doi-asserted-by":"publisher","DOI":"10.1093\/geronb\/63.5.S328"},{"key":"e_1_2_6_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2010.11.006"},{"key":"e_1_2_6_59_1","unstructured":"MunsonJ MordenN GoodmanDet al.The Dartmouth Atlas of Medicare Prescription Drug Use 2013[on\u2010line]. Available athttp:\/\/www.dartmouthatlas.org\/downloads\/reports\/Prescription_Drug_Atlas_101513.pdfAccessed January 3 2016."},{"key":"e_1_2_6_60_1","first-page":"597","article-title":"Dementia in the USA: State variation in prevalence","volume":"37","author":"Koller D","year":"2014","journal-title":"J Pub Health (Oxf)"},{"key":"e_1_2_6_61_1","doi-asserted-by":"crossref","first-page":"W96","DOI":"10.1377\/hlthaff.W2.96","article-title":"Geography and the debate over Medicare reform","author":"Wennberg J","year":"2002","journal-title":"Health Aff"},{"key":"e_1_2_6_62_1","first-page":"1","article-title":"Technology growth and expenditure growth in health care","volume":"2","author":"Chandra A","year":"2011","journal-title":"Natl Bur Econ Res Bull Aging Health"},{"key":"e_1_2_6_63_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000285287.99923.3c"},{"key":"e_1_2_6_64_1","doi-asserted-by":"publisher","DOI":"10.1159\/000146251"},{"key":"e_1_2_6_65_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.287.16.2090"},{"key":"e_1_2_6_66_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.2011.01730.x"},{"key":"e_1_2_6_67_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.160.19.2964"},{"key":"e_1_2_6_68_1","unstructured":"CMS.Partnership to Improve Dementia Care in Nursing Homes Antipsychotic Drug Use in Nursing Homes Trend Update.2014:5\u20138. Available athttps:\/\/www.cms.gov\/Outreach-and-Education\/Outreach\/NPC\/Downloads\/2014-10-27-Trends.pdfAccessed April 1 2016."},{"key":"e_1_2_6_69_1","doi-asserted-by":"publisher","DOI":"10.1002\/gps.2204"},{"key":"e_1_2_6_70_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1497.2005.0126.x"},{"key":"e_1_2_6_71_1","doi-asserted-by":"publisher","DOI":"10.2147\/CIA.S1802"}],"container-title":["Journal of the American Geriatrics Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjgs.14226","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjgs.14226","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/agsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jgs.14226","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T14:09:21Z","timestamp":1762178961000},"score":1,"resource":{"primary":{"URL":"https:\/\/agsjournals.onlinelibrary.wiley.com\/doi\/10.1111\/jgs.14226"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,24]]},"references-count":70,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["10.1111\/jgs.14226"],"URL":"https:\/\/doi.org\/10.1111\/jgs.14226","archive":["Portico"],"relation":{},"ISSN":["0002-8614","1532-5415"],"issn-type":[{"value":"0002-8614","type":"print"},{"value":"1532-5415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,24]]}}}